Clinical significance of axillary findings in patients with lymphoma during follow-up with F-fluorodeoxyglucose-PET

Nuclear Medicine Communications

Volumn 29, Issue 8, 2008, Pages 705-710

  Tsamita, Charoula S ^a   Golemi, Arber ^a   Egesta, Lapci ^a   Castellucci, Paolo ^a   Nanni, Cristina ^a   Stefoni, Vittorio ^b   Grassetto, Gaia ^b   Rubello, Domenico ^b   Tani, Monica ^b   Zinzani, Pier Luigi ^b   Fanti, Stefano ^b  

^a Department of Nuclear Medicine ^*  (Belgium)

^b VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

Author keywords

Clinical significance during follow up; Fluorodeoxyglucose PET axillary finding; Lymphoma patients

Indexed keywords

DIAGNOSTIC AGENT; FLUORODEOXYGLUCOSE F 18; RADIOPHARMACEUTICAL AGENT;

ARTICLE; ECHOGRAPHY; FOLLOW UP; HODGKIN DISEASE; HUMAN; NONHODGKIN LYMPHOMA; POSITRON EMISSION TOMOGRAPHY; RADIOGRAPHY; RETROSPECTIVE STUDY; SCINTISCANNING; AXILLARY LYMPH NODE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; FALSE POSITIVE RESULT; FEMALE; HISTOPATHOLOGY; HUMAN TISSUE; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; RECURRENCE RISK;

FLUORODEOXYGLUCOSE F18; FOLLOW-UP STUDIES; HODGKIN DISEASE; HUMANS; LYMPHOMA, NON-HODGKIN; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; RETROSPECTIVE STUDIES;

EID: 55249124992     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1097/MNM.0b013e328301836d     Document Type: Article

References (21)

1. Altamirano J. Staging, response to therapy, and restaging of lymphomas with (18) F-FDG PET. Arch Med Res 2008; 39:69-77.
2. Kumar R, Maillard I, Schuster DY, Alavi A. Utility of fluorodeoxyglucose-PET imaging in the management of patients with Hodgkin's and non-Hodgkin's lymphomas. Radiol Clin North Am 2004; 42:1083-1100.
3. Burton C, Ell E, Linch D. The role of PET imaging in lymphoma. Br Haematol 2004; 126:772-784.
4. Isasi CR, Lu P, Blaufox MD. A metaanalysis of 18F-2-deoxy-2-fluoro-D-glucose positron emission tomography in staging and restaging of patients with lymphoma. Cancer 2005; 104:1066-1074.
5. Kubota R, Yamada S, Kubota K. Intratumoral distribution of fluorine-18-fluorodeoxyglucose in vivo: high accumulation in macrophages and granulation tissues studied by microautoradiography. J Nucl Med 1992; 33:1972-1980.
6. Kubota R, Kubota K, Yamada S. Microautoradiographic study for the differentiation of intratumoral macrophages, granulation tissues and cancer cells by the dynamics of fluorine-18-fluorodeoxyglucose uptake. J Nucl Med 1994; 35:104-112.
7. Sonet A, Graux C, Nollevaux MC, Krug B, Bosly A, Vander Borght T. Unsuspected FDG-PET findings in the follow-up of patients with lymphoma. Ann Hematol 2007; 86:9-15.
8. Sonet A, Vander Borght T, Graux C, Bosly A. Unsuspected findings identified by FDG-PET study of patients with lymphoma. Hematol J 2003; 4:259-263.
9. Jerusalem G, Beguin Y, Fassotte MF. Early detection of relapse by whole-body positron emission tomography in the follow-up of patients with Hodgkin's disease. Ann Oncol 2003; 14:123-130.
10. Weeks J, Yeap B, Canellos G, Shipp M. Value of follow-up procedures in patients with large-cell lymphoma who achieve a complete remission. J Clin Oncol 1991; 9:1196-1203.
11. Rhodes MM, Delbeke D, Whitlock JA. Utility of FDG-PET/CT in follow-up of children treated for Hodgkin and non-Hodgkin lymphoma. J Pediatr Hematol Oncol 2006; 28:300-306.
12. Hernandez-Pampaloni M, Takalkar A, Yu JQ. F-18 FDG-PET imaging and correlation with CT in staging and follow-up of pediatric lymphomas. Pediatr Radiol 2006; 36:524-531.
13. Barrington SF, O'Doherty MJ. Limitations of PET for imaging lymphoma. Eur J Nucl Med Mol Imaging 2003; 30 (Suppl 1):s117-s127.
14. Castellucci P, Zinzani P, Pourdehnad M. 18F-FDG in malignant lymphoma: significance of positive findings. Eur J Nucl Med Mol Imaging 2005; 32:749-756.
15. Zijlstra JM, Comans EF, van Lingen A. FDG PET in lymphoma: the need for standardization of interpretation. An observer variation study. Nucl Med Commun 2007; 28:798-803.
16. Kline R. PET Scan hypermatabolism induced by influenza vaccination in a patient with non-hodgkin lymphoma. Pediatr Blood Cancer 2006; 46:389-391.
17. Williams G, Joyce RM, Parker JA. False-positive axillary lymph node on FDG-PET/CT scan resulting from immunization. Clin Nucl Med 2006; 31:731-732.
18. Chiang SB, Rebenstock A, Guan L. Potential false-positive FDG PET imaging caused by subcutaneous radiotracer infiltration. Clin Nucl Med 2003; 28:786-788.
19. Muthukrishnan A, Joyce JM, Islam M. Follicular hyperplasia: a potential false-positivity finding on PET/CT imaging in the evaluation of lymphoma. Clin Nucl Med 2006; 31:401-402.
20. Andre M, Mounier N. Second cancers and late toxicities after treatment of aggressive non-Hodgkin lymphoma with the ACVBP regimen: a GELA cohort study on 2837 patients. Blood 2004; 103:1222-1228.
21. Andre M, Henry-Amar M. Treatment-related deaths and second cancer risk after autologous stem-cell transplantation for Hodgkin's disease. Blood 1998; 92:1933-1940.